Mandate

CapMan Oy and 3i Group – sale of NeoPharma AB to Solvay Pharmaceuticals

May 10, 2005

Solvay Pharmaceuticals, the Belgium based pharmaceuticals firm, has agreed to acquire NeoPharma AB, the Sweden based pharmaceuticals firm involved in development of drugs for the treatment of Parkinson's disease, from 3i Group plc, the UK based private equity firm, and CapMan, the Finnish private equity firm, in a transaction, for approximately SEK 640m (EUR 71.26m).

Vinge acted for the sellers, being private investors as well as private equity funds including 3i and CapMan.
Anders Åberg, Malin Ohlin Åkermark (reponsible partners)
Maja Wettergren, Ola Sandersson (associates)

Related

Vinge advises the sellers on the sale of Nextory to Bonnier Books

Vinge has acted as legal adviser to the sellers in connection with Bonnier Books’ acquisition of Nextory, one of Europe’s leading streaming services for audiobooks and e-books. Bonnier Books is acquiring all shares in Nextory, and the transaction comprises Nextory’s operations in Sweden and internationally. The acquisition is a cash transaction and the parties have agreed not to disclose the purchase price. The transaction is subject to customary regulatory approvals.
September 02, 2026

Vinge has advised Nimlas in connection with six strategic acquisitions that strengthen the group's position in the Swedish installation market

Nimlas, with KLAR Partners as majority owner, is one of the Nordic region's leading installation groups, comprising close to 140 companies and 5,000 employees in Sweden, Finland and Norway.
September 02, 2026

Vinge has advised Aspira Partners on the establishment of Aspira Fund I

Vinge has advised Aspira Partners ("Aspira") on the establishment and fundraising of Aspira's inaugural blind-pool fund, Aspira Fund I (D) AB and Aspira Fund I (E) AB (collectively, "Fund I" or the "Fund").
August 31, 2026